Physician profile
Gregory H Downer
NPI 1285635367
$300.28
in general payments reported to CMS, 2019-2025
9 companies · $86.36 in 2025
The $86.36 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.97 · 2020: $13.86 · 2021: $23.70 · 2022: $39.50 · 2023: $92.57 · 2024: $27.32 · 2025: $86.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $191 · Education: $15.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $191.03 |
| Education | $15.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $80.98 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $57.37 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $34.06 | 2025 | Voyxact |
| Ardelyx, INC. | $26.77 | 2023 | Ibsrela |
| Amgen INC. | $25.17 | 2023 | Tavneos |
| Medtronic, INC. | $24.05 | 2025 | Symplicity G3 |
| Aurinia Pharma U.S., INC. | $19.69 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.97 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.22 | 2023 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Downer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.